Literature DB >> 8077678

Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts.

M L Alegre1, L J Peterson, D R Jeyarajah, M Weiser, J A Bluestone, J R Thistlethwaite.   

Abstract

Previous studies have shown that human hemopoietic cells can be adoptively transferred into immunodeficient C.B-17 scid/scid (SCID) mice that lack autologous T and B lymphocytes, to generate chimeric animals. The future development of novel immunomodulatory drugs in transplantation will depend increasingly on experimental animal models to investigate the properties of the agents on human cells before starting clinical trials. However, in previous models of SCID mice engrafted with human PBLs, human T cells have been found either to be in an unresponsive state, unable to respond to mitogenic stimulations in vitro, or to mediate skin graft rejection only when HLA-primed in vivo before their adoptive transfer into SCID mice. In addition, T cells and other leukocyte subsets engraft quite poorly in the lymphoid tissues of the animals. In an attempt to develop a useful model for transplantation research, we have inoculated SCID mice with fresh human splenocytes from cadaveric organ donors (hu-Spl-SCID mice). In this model, various leukocyte subsets engraft effectively in different lymphoid compartments. In addition, human T cells retain their proliferative responses to mitogens and to alloantigens when tested 3 wk after engraftment into SCID mice. Finally, mice engrafted with unprimed human spleen cells acutely reject human foreskin allografts. Treatment of hu-Spl-SCID mice with OKT3, an immunosuppressive mAb directed against the human CD3 complex associated with the TCR, prevents the rejection of most human skin allografts, indicating a major role for human T cells in this phenomenon. Thus, this hu-Spl-SCID model may be useful for the study of immunosuppressive therapies in a preclinical in vivo setting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077678

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras.

Authors:  M Christofidou-Solomidou; S M Albelda; F C Bennett; G F Murphy
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Tetanus toxoid-specific T cell responses in severe combined immunodeficiency (SCID) mice reconstituted with human peripheral blood lymphocytes.

Authors:  R Somasundaram; L Jacob; D Herlyn
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

3.  Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.

Authors:  C Gysemans; M Waer; J Laureys; J Depovere; D Pipeleers; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 4.  Human allograft rejection in humanized mice: a historical perspective.

Authors:  Michael A Brehm; Leonard D Shultz
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

5.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

6.  Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin.

Authors:  A G Murray; J S Schechner; D E Epperson; P Sultan; J M McNiff; C C Hughes; M I Lorber; P W Askenase; J S Pober
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

7.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

8.  Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.

Authors:  Stéphanie Ghosn; Soulaima Chamat; Eric Prieur; Antoine Stephan; Pierre Druilhe; Hasnaa Bouharoun-Tayoun
Journal:  Front Immunol       Date:  2018-03-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.